AGRX

Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by M-Vest. Full details on the panel are as follows:

• Date/Time: Wednesday, July 13, 2022 at 11:00 a.m. ET
• Panel Title: “A Tipping Point in Women’s Health - Does the SCOTUS Outcome Change the Paradigm in Contraception?”
• Moderator: Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research – Equity Research at Maxim Group
• Participating Panelists:
  • Al Altomari, CEO, Agile Therapeutics, Inc. (AGRX)
  • Sabrina Martucci Johnson, CEO, Daré Bioscience, Inc. (DARE)
  • Kathy Lee-Sepsick, CEO, Femasys Inc. (FEMY)

The panel will be hosted on Maxim’s M-Vest website and available to its members. For more information, please visit https://m-vest.com/events/womens-health-panel-07132022.

The webcast of the event will be available on the investor relations page of the Company’s website at https://ir.agiletherapeutics.com/events-and-presentations. The archived webcast will be available from July 15-July 28, 2022.

About Agile Therapeutics, Inc.Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women.  Twirla and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.  Twirla® and our pipeline products are based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at  www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.

Forward-Looking StatementCertain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to the Company’s financial status, the growth of Twirla and the momentum of such growth, the success of the Company’s key initiatives and their effect on the Company’s results, and the execution of the Company’s commercial plan. We may, in some cases use terms such as “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties, including statements regarding the growth in prescriptions and demand for Twirla, the execution of our commercial and business plan, and the contribution of certain elements of our business plan to continued growth in Twirla prescription demand. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including risks related to our ability maintain regulatory approval of Twirla, our ability to successfully commercialize Twirla, regulatory and legislative developments in the United States and foreign countries, our ability to obtain and maintain intellectual property protection for Twirla, our strategy, business plans and focus, and the other risks set forth in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.  For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Contact: Matt RileyHead of Investor Relationsmriley@agiletherapeutics.com